Form 4: Rocket Pharma General Counsel Sells Shares
Insider Transaction Report
Rocket Pharmaceuticals' General Counsel, Martin Wilson, sold 1,646 shares of common stock at $2.983 per share.
Summary
- Martin Wilson, General Counsel of Rocket Pharmaceuticals, Inc. (RCKT), reported a sale of common stock.
- The transaction involved the disposition of 1,646 shares of common stock.
- The shares were sold at a price of $2.983 per share.
- Following this transaction, Martin Wilson beneficially owns 383,816 shares of common stock.
- The reported holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.
- The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, the transaction was conducted under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on new, material non-public information. The volume of shares sold is also relatively small for a public company.
Positives
- The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate, non-public information.
Negatives
- An insider, the General Counsel, reduced their direct beneficial ownership by selling 1,646 shares of common stock.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's stock activity within Rocket Pharmaceuticals.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was conducted under a Rule 10b5-1(c) plan, which is a pre-arranged trading plan designed to allow insiders to sell company stock without violating insider trading laws. | 11/18/2025 | This indicates adherence to corporate governance best practices regarding insider trading, providing an affirmative defense against claims of trading on material non-public information. |
Stakeholder Impact
- Shareholders: A minor reduction in insider ownership, potentially viewed neutrally given the 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 11/18/2025 | Date of transaction (sale of common stock) |
| 11/20/2025 | Date of filing |
Keywords
Rocket Pharmaceuticals, RCKT, Insider Trading, Form 4, Stock Sale, Martin Wilson, General Counsel, Equity Transaction, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.